MUSTO, Pellegrino
MUSTO, Pellegrino
DIPARTIMENTO DI MEDICINA DI PRECISIONE E RIGENERATIVA E AREA JONICA DiMePRe-J
"Hemolysis, or not hemolysis, that is the question". Use of hydroxychloroquine in a patient with COVID-19 infection and G6PD deficiency
2020-01-01 Sgherza, N.; Dalfino, L.; Palma, A.; Vitucci, A.; Campanale, D.; Grasso, S.; Musto, P.
18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease
2016-01-01 Zamagni, E; Nanni, C; Gay, F; Pezzi, A; Patriarca, F; Bellò, M; Rambaldi, I; Tacchetti, P; Hillengass, J; Gamberi, B; Pantani, L; Magarotto, V; Versari, A; Offidani M, ; Zannetti, B; Carobolante, F; Balma, M; Musto, P; Rensi, M; Mancuso, K; Dimitrakopoulou-Strauss, A; Chauviè, S; Rocchi, S; Fard, N; Marzocchi, G; Storto, G; Ghedini, P; Palumbo, A; Fanti, S; Cavo, M
90Y-ibritumomab tiuxetan as consolidation therapy after autologous stem cell transplantation in aggressive non-Hodgkin lymphoma
2011-01-01 Ria, R; Musto, P; Reale, A; Guariglia, R; Iodice, G; Dammacco, F; Vacca, A
90y-ibritumomab tiuxetan as consolidation therapy after autologous stem cell trasplantation in aggressive non-Hodgkin lymphoma
2011-01-01 Ria, Roberto; Musto, P; Reale, A; Guariglia, R; Iodice, G; Dammacco, F; Vacca, Angelo
A reduced intensity conditioning regimen for allografting following autografting is feasible and has strong anti-myeloma activity
2005-01-01 Carella, Am; Beltrami, G; Corsetti, Mt; Scalzulli, P; Carella AM, Jr; Musto, P
A case of acute promyelocytic leukemia variant with derivative chromosome 3 der(3)t(3;8) associated with 8q partial gain
2019-01-01 Nozza, F.; Vona, G.; Trino, S.; D'Auria, F.; La Rocca, F.; Grieco, V.; Possidente, L.; De, Luca; Musto, P.
A comparative analysis of biosimilar vs originator filgrastim in combination with plerixafor for stem cell mobilization in lymphoma and multiple myeloma; a propensity-score weighted multicenter approach.
2017-01-01 Lanza, F; Saraceni, F; Pezzi, A; Martino, M; Bosi, A; Cascavilla, N; Musto, P; Zuffa, E; Tani, M; Cellini, C; Laszlo, D; Bonifazi, F; GITMO (Italian Society, for Transplantation).
A compendium of DIS3 mutations and associated transcriptional signatures in plasma cell dyscrasias
2015-01-01 Lionetti, M; Barbieri, M; Todoerti, K; Agnelli, L; Fabris, S; Tonon, G; Segalla, S; Cifola, I; Pinatel, E; Tassone, P; Musto, P; Baldini, L; Neri, A
A Crumbled but Fatal Acute Leukemia
2022-01-01 Tarantini, F.; Cumbo, C.; Specchia, G.; Musto, P.; Albano, F.
A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma
2008-01-01 Musto, P; Petrucci, Mt; Bringhen, S; Guglielmelli, T; Caravita, T; Bongarzoni, V; Andriani, A; D'Arena, G; Balleari, E; Pietrantuono, G; Boccadoro, M; Palumbo, A
A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma (Cancer (2008) 113, (1588-1595))
2008-01-01 Musto, P.; Petrucci, M. T.; Bringhen, S.; Guglielmelli, T.; Caravita, T.; Bongarzoni, V.; Andriani, A.; D'Arena, G.; Balleari, E.; Pietrantuono, G.; Boccadoro, M.; Palumbo, A.
A pilot characterization of human lung NSCLC by protein pathway activation mapping
2012-01-01 Zupa, A; Improta, G; Silvestri, A; Pin, E; Deng, J; Aieta, M; Musto, P; Nitti, D; Mammano, E; Liotta, L; Belluco, C; Wulfkuhle, J; Petricoin, E 3rd
A Pyrazolo[3,4-d]pyrimidine compound inhibits Fyn phosphorylation and induces apoptosis in natural killer cell leukemia.
2016-01-01 Laurenzana, I; Caivano, A; Trino, S; De Luca, L; La Rocca, F; Simeon, V; Tintori, C; D'Alessio, F; Teramo, A; Zambello, R; Traficante, A; Maietti, M; Semenzato, G; Schenone, S; Botta, M; Musto, P; Del Vecchio, L
A randomized trial with melphalan and prednisone versus melphalan and prednisone plus thalidomide in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplant
2011-01-01 Sacchi, S; Marcheselli, R; Lazzaro, A; Morabito, F; Fragasso, A; Di Renzo, N; Balleari, E; Neri, S; Quarta, G; Ferrara, R; Vigliotti, Ml; Polimeno, G; Musto, P; Consoli, U; Zoboli, A; Buda, G; Pastorini, A; Masini, L
A real-world analysis of PD1 blockade from the Rete Ematologica Pugliese (REP) in patients with relapse/refractory Hodgkin’s lymphoma
2023-01-01 Gaudio, Francesco; Loseto, Giacomo; Bozzoli, Valentina; Scalzulli, Potito Rosario; Mazzone, Anna Maria; Tonialini, Lorenzo; Fesce, Vincenza; Quintana, Giovanni; De Santis, Gaetano; Masciopinto, Pierluigi; Arcuti, Elena; Clemente, Felice; Scardino, Stefania; Tarantini, Giuseppe; Pastore, Domenico; Melillo, Lorella; Pavone, Vincenzo; Maggi, Alessandro; Carella, Angelo Michele; Di Renzo, Nicola; Guarini, Attilio; Musto, Pellegrino
A shorter time to the first treatment may be predicted by the absolute number of regulatory T-cells in patients with Rai stage 0 chronic lymphocytic leukemia
2012-01-01 D'Arena, G; D'Auria, F; Simeon, V; Laurenti, L; Deaglio, S; Mansueto, G; Principe MI, ; Statuto, T; Pietrantuono, G; Guariglia, R; Innocenti, I; Martorelli, Mc; Villani O, ; De Feo, V; Poeta, Gd; Musto, P
Aberrant activation of ROS1 represents a new molecular defect in chronic myelomonocytic leukemia
2013-01-01 Cilloni, D; Carturan, S; Bracco, E; Campia, V; Rosso, V; Torti, D; Calabrese, C; Gaidano, V; Niparuck, P; Favole, A; Signorino, E; Iacobucci, I; Morano, A; De Luca, L; Musto, P; Frassoni, F; Saglio, G
Absolute monocyte count at diagnosis could improve the prognostic role of early FDG-PET in classical Hodgkin lymphoma patients
2016-01-01 Bari, A; Marcheselli, L; Marcheselli, R; Pozzi, S; Cox, Mc; Baldessari, C; Ferri, P; Gobbi, P; Baldini, L; Tadmor, T; Musto, P; Federico, M; Sacchi, S
ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial
2009-01-01 Federico, M; Luminari, S; Iannitto, E; Polimeno, G; Marcheselli, L; Montanini, A; La Sala, A; Merli, F; Stelitano, C; Pozzi, S; Scalone, R; Di Renzo, N; Musto, P; Baldini L, ; Cervetti, G; Angrilli, F; Mazza, P; Brugiatelli, M; Gobbi, Pg
Accreditation for excellence of cancer research institutes: recommendations from the Italian Network of Comprehensive Cancer Centers
2014-01-01 Deriu, Pl; La Pietra, L; Pierotti, M; Collazzo, R; Paradiso, A; Belardelli, F; De Paoli, P; Nigro, A; Lacalamita, R; Ferrarini, M; Pelicci, P; Pierotti, M; Roli, A; Ciliberto, G; Scala, S; Amadori, A; Chiusole, D; Musto, P; Fusco, V; Storto, G; De, Maria R; Canitano, S; Apolone, G; Ravelli, M; Mazzini, E; Amadori, D; Bernabini, M; Ancarani, V; Lombardo, C
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| "Hemolysis, or not hemolysis, that is the question". Use of hydroxychloroquine in a patient with COVID-19 infection and G6PD deficiency | 1-gen-2020 | Sgherza, N.; Dalfino, L.; Palma, A.; Vitucci, A.; Campanale, D.; Grasso, S.; Musto, P. | |
| 18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease | 1-gen-2016 | Zamagni, E; Nanni, C; Gay, F; Pezzi, A; Patriarca, F; Bellò, M; Rambaldi, I; Tacchetti, P; Hillengass, J; Gamberi, B; Pantani, L; Magarotto, V; Versari, A; Offidani M, ; Zannetti, B; Carobolante, F; Balma, M; Musto, P; Rensi, M; Mancuso, K; Dimitrakopoulou-Strauss, A; Chauviè, S; Rocchi, S; Fard, N; Marzocchi, G; Storto, G; Ghedini, P; Palumbo, A; Fanti, S; Cavo, M | |
| 90Y-ibritumomab tiuxetan as consolidation therapy after autologous stem cell transplantation in aggressive non-Hodgkin lymphoma | 1-gen-2011 | Ria, R; Musto, P; Reale, A; Guariglia, R; Iodice, G; Dammacco, F; Vacca, A | |
| 90y-ibritumomab tiuxetan as consolidation therapy after autologous stem cell trasplantation in aggressive non-Hodgkin lymphoma | 1-gen-2011 | Ria, Roberto; Musto, P; Reale, A; Guariglia, R; Iodice, G; Dammacco, F; Vacca, Angelo | |
| A reduced intensity conditioning regimen for allografting following autografting is feasible and has strong anti-myeloma activity | 1-gen-2005 | Carella, Am; Beltrami, G; Corsetti, Mt; Scalzulli, P; Carella AM, Jr; Musto, P | |
| A case of acute promyelocytic leukemia variant with derivative chromosome 3 der(3)t(3;8) associated with 8q partial gain | 1-gen-2019 | Nozza, F.; Vona, G.; Trino, S.; D'Auria, F.; La Rocca, F.; Grieco, V.; Possidente, L.; De, Luca; Musto, P. | |
| A comparative analysis of biosimilar vs originator filgrastim in combination with plerixafor for stem cell mobilization in lymphoma and multiple myeloma; a propensity-score weighted multicenter approach. | 1-gen-2017 | Lanza, F; Saraceni, F; Pezzi, A; Martino, M; Bosi, A; Cascavilla, N; Musto, P; Zuffa, E; Tani, M; Cellini, C; Laszlo, D; Bonifazi, F; GITMO (Italian Society, for Transplantation). | |
| A compendium of DIS3 mutations and associated transcriptional signatures in plasma cell dyscrasias | 1-gen-2015 | Lionetti, M; Barbieri, M; Todoerti, K; Agnelli, L; Fabris, S; Tonon, G; Segalla, S; Cifola, I; Pinatel, E; Tassone, P; Musto, P; Baldini, L; Neri, A | |
| A Crumbled but Fatal Acute Leukemia | 1-gen-2022 | Tarantini, F.; Cumbo, C.; Specchia, G.; Musto, P.; Albano, F. | |
| A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma | 1-gen-2008 | Musto, P; Petrucci, Mt; Bringhen, S; Guglielmelli, T; Caravita, T; Bongarzoni, V; Andriani, A; D'Arena, G; Balleari, E; Pietrantuono, G; Boccadoro, M; Palumbo, A | |
| A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma (Cancer (2008) 113, (1588-1595)) | 1-gen-2008 | Musto, P.; Petrucci, M. T.; Bringhen, S.; Guglielmelli, T.; Caravita, T.; Bongarzoni, V.; Andriani, A.; D'Arena, G.; Balleari, E.; Pietrantuono, G.; Boccadoro, M.; Palumbo, A. | |
| A pilot characterization of human lung NSCLC by protein pathway activation mapping | 1-gen-2012 | Zupa, A; Improta, G; Silvestri, A; Pin, E; Deng, J; Aieta, M; Musto, P; Nitti, D; Mammano, E; Liotta, L; Belluco, C; Wulfkuhle, J; Petricoin, E 3rd | |
| A Pyrazolo[3,4-d]pyrimidine compound inhibits Fyn phosphorylation and induces apoptosis in natural killer cell leukemia. | 1-gen-2016 | Laurenzana, I; Caivano, A; Trino, S; De Luca, L; La Rocca, F; Simeon, V; Tintori, C; D'Alessio, F; Teramo, A; Zambello, R; Traficante, A; Maietti, M; Semenzato, G; Schenone, S; Botta, M; Musto, P; Del Vecchio, L | |
| A randomized trial with melphalan and prednisone versus melphalan and prednisone plus thalidomide in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplant | 1-gen-2011 | Sacchi, S; Marcheselli, R; Lazzaro, A; Morabito, F; Fragasso, A; Di Renzo, N; Balleari, E; Neri, S; Quarta, G; Ferrara, R; Vigliotti, Ml; Polimeno, G; Musto, P; Consoli, U; Zoboli, A; Buda, G; Pastorini, A; Masini, L | |
| A real-world analysis of PD1 blockade from the Rete Ematologica Pugliese (REP) in patients with relapse/refractory Hodgkin’s lymphoma | 1-gen-2023 | Gaudio, Francesco; Loseto, Giacomo; Bozzoli, Valentina; Scalzulli, Potito Rosario; Mazzone, Anna Maria; Tonialini, Lorenzo; Fesce, Vincenza; Quintana, Giovanni; De Santis, Gaetano; Masciopinto, Pierluigi; Arcuti, Elena; Clemente, Felice; Scardino, Stefania; Tarantini, Giuseppe; Pastore, Domenico; Melillo, Lorella; Pavone, Vincenzo; Maggi, Alessandro; Carella, Angelo Michele; Di Renzo, Nicola; Guarini, Attilio; Musto, Pellegrino | |
| A shorter time to the first treatment may be predicted by the absolute number of regulatory T-cells in patients with Rai stage 0 chronic lymphocytic leukemia | 1-gen-2012 | D'Arena, G; D'Auria, F; Simeon, V; Laurenti, L; Deaglio, S; Mansueto, G; Principe MI, ; Statuto, T; Pietrantuono, G; Guariglia, R; Innocenti, I; Martorelli, Mc; Villani O, ; De Feo, V; Poeta, Gd; Musto, P | |
| Aberrant activation of ROS1 represents a new molecular defect in chronic myelomonocytic leukemia | 1-gen-2013 | Cilloni, D; Carturan, S; Bracco, E; Campia, V; Rosso, V; Torti, D; Calabrese, C; Gaidano, V; Niparuck, P; Favole, A; Signorino, E; Iacobucci, I; Morano, A; De Luca, L; Musto, P; Frassoni, F; Saglio, G | |
| Absolute monocyte count at diagnosis could improve the prognostic role of early FDG-PET in classical Hodgkin lymphoma patients | 1-gen-2016 | Bari, A; Marcheselli, L; Marcheselli, R; Pozzi, S; Cox, Mc; Baldessari, C; Ferri, P; Gobbi, P; Baldini, L; Tadmor, T; Musto, P; Federico, M; Sacchi, S | |
| ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial | 1-gen-2009 | Federico, M; Luminari, S; Iannitto, E; Polimeno, G; Marcheselli, L; Montanini, A; La Sala, A; Merli, F; Stelitano, C; Pozzi, S; Scalone, R; Di Renzo, N; Musto, P; Baldini L, ; Cervetti, G; Angrilli, F; Mazza, P; Brugiatelli, M; Gobbi, Pg | |
| Accreditation for excellence of cancer research institutes: recommendations from the Italian Network of Comprehensive Cancer Centers | 1-gen-2014 | Deriu, Pl; La Pietra, L; Pierotti, M; Collazzo, R; Paradiso, A; Belardelli, F; De Paoli, P; Nigro, A; Lacalamita, R; Ferrarini, M; Pelicci, P; Pierotti, M; Roli, A; Ciliberto, G; Scala, S; Amadori, A; Chiusole, D; Musto, P; Fusco, V; Storto, G; De, Maria R; Canitano, S; Apolone, G; Ravelli, M; Mazzini, E; Amadori, D; Bernabini, M; Ancarani, V; Lombardo, C |